16 November 2020 

Moderna announced that Switzerland’s healthcare regulator Swissmedic has begun a rolling review of the company’s Covid-19 vaccine candidate mRNA-1273. This is the result of positive data from a preclinical viral challenge study and Phase I interim analysis of the vaccine. The rolling review approach allows Swissmedic to consider data from ongoing clinical trials more expediently.

The Russian Direct Investment Fund (RDIF) and South Korean biotech GL Raph have collaborated to produce more than 150 million doses of the Sputnik V Covid-19 vaccine every year. The parties intend to begin production in December 2020 and begin rolling out the vaccine in January 2021.

NeuroRx and Relief Therapeutics have announced that approximately 150 patients have been enrolled in its ongoing Phase IIb/III trial of RLF-100 (aviptadil) for Covid-19 patients suffering from respiratory failure. The partners’ targeted enrolment total is 165 patients.

Israel and Pfizer have signed a deal for the procurement of 8 million doses of the company’s Covid-19 vaccine, which is enough to treat approximately half of Israel’s population. Pfizer and BioNTech had confirmed a forthcoming deal in earlier statements, but had not disclosed any financial details. The US Food and Drug Administration (FDA) and Israel’s Health Ministry are yet to approve the deal.